Source comparison
Tesamorelin vs Native GHRH: Structural Differences That Matter
Tesamorelin is not bioidentical to human GHRH. It's a synthetic analog with deliberate structural modifications designed to extend functional stability. Native GHRH (GHRH1-44-NH2) consists of 44 amino acids but lacks the trans-3-hexenoic acid modification pres
This comparison does not assign a generated winner or score.
- Tesamorelin is not bioidentical to human GHRH. It's a synthetic analog with deliberate structural modifications designed to extend functional stability. Native GHRH (GHRH1-44-NH2) consists of 44 amino acids but lacks the trans-3-hexenoic acid modification present in tesamorelin. That single addition at the N-terminus drastically alters pharmacokinetics: native GHRH has a plasma half-life under 10 minutes due to rapid DPP-4 cleavage, while tesamorelin's modified structure extends half-life to 26–38 minutes. A threefold improvement.
- The modification doesn't change receptor binding affinity significantly, but it does alter clearance kinetics. Research published in the Journal of Clinical Endocrinology & Metabolism found that tesamorelin produces sustained GH elevation across 120-minute measurement windows, while native GHRH peaks sharply and collapses within 20–30 minutes. That difference is why tesamorelin became the focus of clinical development for visceral adiposity reduction, while native GHRH remained confined to diagnostic testing applications.
- Another critical distinction: tesamorelin is synthesised through solid-phase peptide synthesis (SPPS) under controlled laboratory conditions, ensuring sequence fidelity and purity above 98%. Native GHRH, when used in research, is typically recombinant. Produced in bacterial or yeast expression systems. Which introduces potential for endotoxin contamination and sequence variability. Real Peptides manufactures tesamorelin peptide using SPPS with exact amino-acid sequencing, guaranteeing batch-to-batch consistency that recombinant methods can't match.